Jane Metrik, Nicholas Bush, Rachel L Gunn, Denis M McCarthy
{"title":"Recent Advances in the Science of Cannabis-Impaired Driving.","authors":"Jane Metrik, Nicholas Bush, Rachel L Gunn, Denis M McCarthy","doi":"10.1007/s40429-025-00712-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To examine cannabis-induced effects on driving performance. Prior systematic reviews consistently reveal that Δ⁹-tetrahydrocannabinol (THC) impairs driving performance. The present narrative review summarized evidence on the acute and residual effects of cannabis on driving performance from controlled experimental research completed in the past five years. Expanding on prior research, recent studies examine individual and combined effects of THC and cannabidiol (CBD), combined effects of cannabis and alcohol, and a variety of cannabis administration modes.</p><p><strong>Recent findings: </strong>Cannabis with THC acutely impairs driving without significant residual deficits. CBD does not acutely impair driving performance, although relatively low doses (< 300 mg) were used in most studies. The combination of alcohol and THC results in additive effects that amplifies impairment. In line with prior research findings, cannabis-induced driving impairment is consistently observed within the first hour after use and impairment remains detectable for ~ 4-5 h post-inhalation; studies testing oral and sublingual cannabis administrations were sparse. Participants were willing and ready to drive shortly after using cannabis while their driving skills were objectively impaired.</p><p><strong>Summary: </strong>Despite clear evidence of cannabis-induced driving impairment, a consistent impairment standard that can be used outside the laboratory is lacking. More research focused on sensitive biomarkers combined with technologically-advanced behavioral methods is needed to improve the precision and accuracy in determining cannabis-induced driving impairment. Future studies should focus on novel oral and oromucosal formulations emerging on the legal cannabis market.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"13 1","pages":"8"},"PeriodicalIF":4.6000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12864297/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Addiction Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40429-025-00712-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: To examine cannabis-induced effects on driving performance. Prior systematic reviews consistently reveal that Δ⁹-tetrahydrocannabinol (THC) impairs driving performance. The present narrative review summarized evidence on the acute and residual effects of cannabis on driving performance from controlled experimental research completed in the past five years. Expanding on prior research, recent studies examine individual and combined effects of THC and cannabidiol (CBD), combined effects of cannabis and alcohol, and a variety of cannabis administration modes.
Recent findings: Cannabis with THC acutely impairs driving without significant residual deficits. CBD does not acutely impair driving performance, although relatively low doses (< 300 mg) were used in most studies. The combination of alcohol and THC results in additive effects that amplifies impairment. In line with prior research findings, cannabis-induced driving impairment is consistently observed within the first hour after use and impairment remains detectable for ~ 4-5 h post-inhalation; studies testing oral and sublingual cannabis administrations were sparse. Participants were willing and ready to drive shortly after using cannabis while their driving skills were objectively impaired.
Summary: Despite clear evidence of cannabis-induced driving impairment, a consistent impairment standard that can be used outside the laboratory is lacking. More research focused on sensitive biomarkers combined with technologically-advanced behavioral methods is needed to improve the precision and accuracy in determining cannabis-induced driving impairment. Future studies should focus on novel oral and oromucosal formulations emerging on the legal cannabis market.
期刊介绍:
This journal focuses on the prevention, assessment and diagnosis, and treatment of addiction. Designed for physicians and other mental health professionals who need to keep up-to-date with the latest research, Current Addiction Reports offers expert reviews on the most recent and important research in addiction. We accomplish this by appointing leaders in the field to serve as Section Editors in key subject areas and disciplines, such asAlcoholTobaccoStimulants, cannabis, and club drugsBehavioral addictionsGender disparities in addictionComorbid psychiatric disorders and addictionSubstance abuse disorders and HIVSection Editors, in turn, select the most pressing topics as well as experts to evaluate the latest research, report on any controversial discoveries or hypotheses of interest, and ultimately bring readers up-to-date on the topic. Articles represent interdisciplinary endeavors with research from fields such as psychiatry, psychology, pharmacology, epidemiology, and neuroscience.Additionally, an international Editorial Board—representing a range of disciplines within addiction medicine—ensures that the journal content includes current, emerging research and suggests articles of special interest to their country or region.